GLP-1 RAs联合恩格列净对2型糖尿病患者的治疗效果及对胰岛素抵抗水平分析

Analysis of the Therapeutic Effect of GLP-1 RAs Combined with Enpagliflozin on Patients with Type 2 Diabetes and the Level of Insulin Resistance

目的探讨胰高血糖素样肽-1受体激动剂(GLP-1 RAs)联合恩格列净对2型糖尿病患者的治疗效果及其对胰岛素抵抗水平的影响。方法选取2020年2月—2021年3月该院收治的116例2型糖尿病患者为研究对象,运用随机数表法将其分为研究组和对照组,各58例。予对照组患者恩格列净治疗,研究组患者则在对照组基础上联合GLP-1 RAs进行治疗,两组连续治疗2个月后,评估两组患者临床治疗效果,对比两组患者治疗前后糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)、空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)水平,同时观察两组患者治疗过程中的不良反应发生情况。结果治疗后,研究组患者的FINS水平较对照组高,HbA1c、2 hPG、FPG、HOMA-IR均比对照组低,差异有统计学意义(P<0.05)。研究组治疗总有效率为96.55%,显著高于对照组的84.48%,差异有统计学意义(P<0.05)。研究组不良反应发生率为5.17%低于对照组的17.24%,差异有统计学意义(P<0.05)。结论对2型糖尿病患者患者采用GLP-1 RAs联合恩格列净治疗,疗效确切,可显著降低其血糖水平,改善胰岛功能,并能有效减轻胰岛素抵抗,不良反应发生率较低,较为安全,值得在临床上进一步推广应用。

Objective To investigate the therapeutic effect of glucagon-like peptide-1 receptor agonists(GLP-1 RAs)combined with empagliflozin on patients with type 2 diabetes and its effect on insulin resistance.Methods A total of 116 patients with type 2 diabetes who were admitted to the hospital from February 2020 to March 2021 were selected as the research objects.Using random number table method,they were divided into study group and control group,each with 58 cases.Patients in the control group were treated with empagliflozin,and patients in the study group were treated with GLP-1 RAs on the basis of the control group.After two consecutive months of treatment,the clinical treatment effects of the two groups of patients were evaluated.The levels of glycosylated hemoglobin(HbA1c),2 h postprandial blood glucose(2 hPG),fasting blood glucose(FPG),fasting insulin(FINS),and insulin resistance index(HOMA-IR)before and after treatment were compared between the two groups.At the same time,observed the occurrence of adverse reactions during the treatment of the two groups of patients.Results After treatment,the FINS levels of patients in the study group were higher than those in the control group.HbA1c,2 hPG,FPG,and HOMA-IR were all lower than those in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the study group was 96.55%,which was significantly higher than the 84.48%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 5.17%lower than that in the control group 17.24%,the difference was statistically significant(P<0.05).Conclusion GLP-1 RAs combined with enpagliflozin treatment for patients with type 2diabetes has a definite effect.It can significantly reduce blood glucose levels,improve islet function,and can effectively reduce insulin resistance.The incidence of adverse reactions is relatively low,and it is relatively safe.It is worthy of further promotion and application in clinical practice.